KELOWNA, BC, Oct. 17, 2018 /PRNewswire/ – Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) (“Marapharm” or the “Company”) shares its exhilaration with Canadians on this historic day of the legalization of recreational cannabis.
Health Canada has confirmed receipt of our amended, late-state ACMPR application.
We are strategically positioning ourselves to become a presence in the Canadian cannabis market. Our (10) 10,000 sq. ft bio-secure facilities (100,000 sq. ft) will aim to produce a pure organic cannabis flower using cultivation methods that will leave a small environmental footprint allowing us to produce at a lower cost.
The governmental agency Health Canada estimates annual demand in the country to be 926,000 kilograms, or about 2 million pounds. There’s no reliable data on the exact supply of licensed recreational vendors, however the most recent estimates put the nation’s supply of medical marijuana at 66,404 kilograms of dried cannabis.
“We have shared a common goal for the legalization of cannabis and today it is a reality. We are honoured to be a part of this revolution and now we are free to unlock the potential of this amazing plant.” Linda Sampson, President and CEO
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.